Alpha Cognition Inc. (ACOG)
NASDAQ: ACOG · Real-Time Price · USD
6.98
+0.07 (1.01%)
May 14, 2025, 2:25 PM - Market open
Company Description
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury.
It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, granulin epithelin motifs for the treatment of neurodegenerative diseases.
The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021.
Alpha Cognition Inc. was founded in 2000 and is based in Vancouver, Canada.
Alpha Cognition Inc.
| Country | Canada |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Michael McFadden |
Contact Details
Address: 750 West Pender Street, Suite 1200 Vancouver, BC V6C Canada | |
| Phone | 604 564 9244 |
| Website | alphacognition.com |
Stock Details
| Ticker Symbol | ACOG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001655923 |
| ISIN Number | CA02074J5017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael E. McFadden B.B.A. | Chief Executive Officer and Director |
| Lauren D'Angelo M.B.A. | Chief Operating Officer |
| Kenneth Anthony Cawkell B.A., LL.B. | Founder, Consultant, Corporate Secretary and Director |
| Henry Du C.P.A. | Vice President of Finance and Accounting and Interim Chief Financial Officer |
| Dr. Denis G. Kay Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 6, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2025 | SCHEDULE 13G | Filing |
| Apr 10, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |